Portal de Periódicos da CAPES

Non–Small Cell Lung Cancer

2012; National Comprehensive Cancer; Volume: 10; Issue: 10 Linguagem: Inglês

10.6004/jnccn.2012.0130

1540-1413

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor Ganti, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng‐Ming Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo, Renato Martins, Janis P. O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary Pinder-Schenck, Katherine M.W. Pisters, Karen L. Reckamp, Gregory J. Riely, Eric Rohren, Steven Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, Kristina M. Gregory,

Cancer Diagnosis and Treatment

Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify patients with metastatic disease before initiating aggressive treatment, thus sparing these patients from unnecessary futile treatment. If metastatic disease is discovered during surgery, then extensive surgery is often aborted. Decisions about treatment should be based on multidisciplinary discussion.